Skip to main content

Table 1 Characteristics of patient interview participants (n = 25)

From: Patient and clinician experiences with the implementation of telemedicine and related adaptations in office-based buprenorphine treatment during the COVID-19 pandemic: a qualitative study

 

n (%)

Age (Mean, SD)

49 (11)

   Age Range

32–67

Gender Identity

 

   Male

16 (64%)

   Female

9 (36%)

English as Primary Language

24 (96%)

Race/Ethnicity

 

   Black, Non-Hispanic

7 (28%)

   White, Non-Hispanic

16 (64%)

   Other

2 (8%)

Housing Status

 

   Unstable (e.g. street/outdoors, shelter, etc.)

4 (16%)

   Stable (e.g. own/rent, supportive housing, etc.)

21 (84%)

Education Level

 

   Elementary-High School

16 (64%)

   College/Technical School

9 (36%)

Employment Status

 

   Employed/Student

13 (52%)

   Unemployed, Disabled, or Retired

12 (48%)

Insurance Status

 

   Medicaid

19 (76%)

   Medicare

4 (16%)

   Private

2 (8%)

Prescribed Medication for Opioid Use Disorder

 

   Sublingual Buprenorphine

22 (88%)

   Injectable Buprenorphine

3 (12%)